Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Hemostatic Disorders

• The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin
• Heparin Reversal With Two Different Protamine Ratios After Cardiopulmonary By-pass.
• Recombinant vWF Concentrate and ECMO
• Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy
• Tranexamic Acid Administration Strategies in Cardiovascular Surgery: Goal-directed vs. Empirical Tranexamic Acid Administration
• Prevention of Cefoperazone-induced Coagulopathy
• Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery
• Coagulation and Fibrinolysis of Estradiol in Transwomen
• The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
• The Influence of Tramadol on Platelet Function
• Safety and Feasibility of Argatroban as Anticoagulant in Adults With ECMO
• A Trial of PROTHROMPLEX TOTAL for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation
• Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
• BT200 in Hereditary Bleeding Disorders
• Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study
• Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection
• Palonosetron and Blood Coagulation
• Ondansetron and Blood Coagulation
• A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic
• The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications
• RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM
• Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage
• High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy
• Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
• Covid-19 Associated Coagulopathy
• A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE)
• Safety and Efficacy of Edoxaban in Thoracoscopic Ablation
• Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.
• Fibrinogen Concentrate In Children Cardiac Surgery 2
• XIENCE 28 USA Study
• A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
• IV Ketorolac on Platelet Function Post-Cesarean Delivery
• NOAC Plasma Concentration and Blood Coagulation in Healthy Volunteers
• Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication
• Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)
• Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis
• A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A
• The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
• Fibrinogen Early In Severe Trauma studY Junior
• Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period
• XIENCE 28 Global Study
• Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery
• Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin
• Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus
• A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
• Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban
• A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
• Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
• Thromboelastometry in Liver Transplantation
• Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A
• Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
• Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
• A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Sev
• Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial
• Human Fibrinogen Concentrate in Pediatric Cardiac Surgery
• Major Liver Resection: Early Clotting Disorders and Functional Impairment.
• The Effect of Voltaren-ophtha 0.1% Eye Drops on INR Levels (International Normalized Ratio) in Patients Taking Warfarin
• CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients
• Freeze-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients
• Fibrinogen Early In Severe Trauma studY
• A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan
• Colloid Pre-Loading on D-Dimer During Cesarean Section Under Spinal Anesthesia
• PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
• Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions
• Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
• Hemostatic Complications in Hematopoietic Stem Cell Transplantation
• The Effect of Human Albumin on Coagulation Competence and Hemorrhage
• Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
• To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
• Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)
• The Clinical Study of Atorvastatin and Dexamethasone on Treatment for Chronic Subdural Hematoma in the Patients With Coagulation Disorders
• Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)
• Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
• Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
• Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
• Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects
• Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
• Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery
• A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
• The Effects of Enzymes and Flavonoids on Inflammation and Coagulation After Marathon
• Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma
• A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
• Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study
• Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers
• Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers
• A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors
• A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
• Treatment of Congenital Factor VII Deficiency
• A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
• Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A
• Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding
• A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
• Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
• Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction
• Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
• An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients
• Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers
• Anfibatide Phase 1 Clinical Trial in Healthy Volunteers
• Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
• Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery
• Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice
• Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage
• Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation
• Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients
• Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers
• Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation
• Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
• Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
• Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
• Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
• Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
• Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
• Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
• Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
• Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
• Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects
• RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma
• Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants
• Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
• Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
• Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.
• Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
• Observational Registry of the Treatment of Glanzmann's Thrombasthenia
• Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
• Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
• Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
• Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
• A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A
• Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
• Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
• Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency
• Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients
• Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia
• Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects
• Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
• A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
• Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
• Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency
• Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
• Study Using Plasma for Patients Requiring Emergency Surgery
• Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
• Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
• Fibrinogen Concentrate In Children After Cardiac Surgery
• Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers
• Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
• Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects
• Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
• Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
• Anticoagulant Clinics and Vitamin K Antagonists
• Clinical and Economic Implications of Genetic Testing for Warfarin Management
• Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
• A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers
• Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
• Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B
• Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
• The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders
• PROPACT: Retrospective Prophylaxis Patient Case Collection
• Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database
• Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
• Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects
• Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers
• Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction
• Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
• Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
• Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
• The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders
• Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
• The Effect of the Mini-pill on Blood Factors in Women at Increased Risk for Forming Blood Clots
• High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors
• Dilutional Coagulopathy in Patients Undergoing Elective Surgery
• Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
• Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
• PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care
• Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
• Factor VIIa in Acute Intracerebral Haemorrhage
• "Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
• Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
• Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
• Use of NovoSeven® in Active Variceal Bleeding
• Use of Activated Recombinant Human Factor VII in Cardiac Surgery
• Oral Vitamin K for Warfarin Associated Coagulopathy
• Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
• Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
• Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
• Treatment and Management of Women With Bleeding Disorders
• Trial of NovoSeven® in Haemophilia - Joint Bleeds
• Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
• Dose Response to Recombinant Factor VIIa When Administered for Bleed
• Use of Activated Recombinant FVII in Spinal Surgery
• Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
• Cooperative Study of Factor VIII Inhibitors